Additional file 1 of Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood–brain-barrier penetration and tumor microenvironment modulation

Additional file 1: Fig. S1. Stability and characterization of GENs. Fig. S2. Characterization of GENs. Fig. S3. Transwell of C6 glioma cells and BCECs. Fig. S4. Blocking BBB endocytosis of DiD-labeled GENs in C6 glioma cells in vitro. Fig. S5. Cell viability of GENs was individually evaluated by MTT assay in C6 glioma, 3T3, RAW 264.7, and HUVEC. Fig. S6. Western blotting of protein expression of apoptosis-related proteins with sequential reduction of GENs’ concentrations from 62.5 to 0.24 μg/mL. Fig. S7. Inhibition of endocytosis of GENs with chemical inhibitors in C6 glioma cell. Fig. S8. Blood chemistry analysis in serum in vivo. Fig. S9. Flow cytometry analysis of CD86 expression in RAW 264.7 with the treatment of different concentrations of GENs. Fig. S10. A pie chart of miRNA abundance in GENs. Fig. S11. A pie chart of the ten most abundant miRNAs in GENs. Fig. S12. Lipid extraction from GENs and the exosomal delivery of miRNAs. Fig. S13. Encapsulation of miRNA in GENs. Fig. S14. Enriched gene ontology (GO) terms (hsa). Fig. S15. Gene Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of GENs. Table S1. Primer set list. Table S2. RNA Profiling Analysis. Table S3. Protein profiles of GENs. Table S4. hsa.DEG_GO_enrichment_result. Table S5. Readcount_TPM

附加文件1：
图S1：GENs的稳定性与表征
图S2：GENs的表征
图S3：C6胶质瘤细胞与BCECs的Transwell实验
图S4：体外C6胶质瘤细胞中DiD标记GENs的血脑屏障（BBB）内吞作用阻断实验
图S5：采用MTT法分别评估GENs在C6胶质瘤细胞、3T3细胞、RAW 264.7细胞及人脐静脉内皮细胞（HUVEC）中的细胞活力
图S6：以62.5~0.24 μg/mL梯度递减GENs浓度，检测凋亡相关蛋白表达的蛋白质印迹实验
图S7：C6胶质瘤细胞中化学抑制剂对GENs内吞作用的抑制实验
图S8：体内血清血液生化分析
图S9：不同浓度GENs处理RAW 264.7细胞后CD86表达的流式细胞术分析
图S10：GENs中miRNA丰度的饼图
图S11：GENs中丰度排名前十的miRNA的饼图
图S12：GENs的脂质提取与miRNA的外泌体递送
图S13：GENs对miRNA的包封
图S14：富集的基因本体（GO）条目（hsa）
图S15：GENs的京都基因与基因组百科全书（KEGG）富集分析
表S1：引物序列列表
表S2：RNA谱分析
表S3：GENs的蛋白质谱
表S4：hsa.DEG_GO_enrichment_result
表S5：读取计数与每百万转录本数（Readcount_TPM）